An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b

Trial Profile

An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2016

At a glance

  • Drugs Brivaracetam (Primary)
  • Indications Epilepsy
  • Focus Registrational; Therapeutic Use
  • Sponsors UCB Pharma SA
  • Most Recent Events

    • 25 Apr 2015 Results presented at the 67th Annual Meeting of the American Academy of Neurology.
    • 01 Nov 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Jun 2013 Planned end date changed from 1 Oct 2014 to 1 Apr 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top